Monitor for upcoming clinical milestones for BETR-001 (migraine/headache disorders) and any further capital raises, as the company's going-concern status and minimal cash ($12,570 as of Jan 31, 2026) necessitate near-term financing. The director appointment adds governance credibility but does not change the fundamental cash runway risk.
Price Chart
Executive Summary
BetterLife Pharma appointed Charles Duncan, PhD as Director and Chair of the Audit Committee, granted him 625,000 stock options, and reported $127,500 in gross proceeds from the exercise of 850,000 warrants at $0.15/share. The filing is routine governance and capital-raising activity for a pre-revenue biotech with a going-concern qualification, lacking material financial data or clinical catalysts.
Key Facts
- Appointed Charles Duncan, PhD as Director and Chair of the Audit Committee.
- Granted 500,000 stock options (exercise price $0.285, quarterly vesting over 24 months, 10-year term) and 125,000 stock options (exercise price $0.285, vesting over 3 months, 10-year term).
- Received $127,500 gross proceeds from exercise of 850,000 warrants at $0.15 per share from September 1-10, 2026.
- Approved Amended and Restated Long-term Incentive Plan on August 27, 2026.
- Company has no revenue, negative cash flow from operations, current liabilities exceeding current assets, and an accumulated deficit — going-concern qualification per the 20-F filed June 2026.
Financial Impact
Gross proceeds of $127,500 from warrant exercises; no revenue or earnings reported in this filing.
Risk Factors
- Going-concern risk: no revenue, negative cash flow, current liabilities exceed current assets.
- Dilution from stock option grants (625,000 shares) and warrant exercises (850,000 shares).
- Pre-revenue clinical-stage biotech with no approved products or near-term catalysts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001477932-26-005526 |
| Document: betrf_6k.htm | 0001477932-26-005526 |
| Document: 0001477932-26-005526-index-headers.html | 0001477932-26-005526 |
| Document: 0001477932-26-005526-index.html | 0001477932-26-005526 |
| Document: 0001477932-26-005526.txt | 0001477932-26-005526 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 26d ago | 6-K | $0.2410 $0.1920 | ▼ −20.33% | ▼ −22.25% | $0.1700 (−29.46%) |
Sep 22, 2026 4w ago | SC 13G | $0.2400 $0.2410 | ▲ +0.42% | ▲ +1.09% | $0.1700 (−29.17%) |
Sep 15, 2026 5w ago | 6-K | $0.2740 $0.2217 | ▼ −19.09% | ▼ −19.91% | $0.1700 (−37.96%) |
Sep 11, 2026 6w ago | 6-K | $0.2300 $0.2550 | ▲ +10.87% | ▲ +11.09% | $0.1700 (−26.09%) |
Aug 24, 2026 9w ago | 6-K | $0.2240 $0.2195 | ▼ −2.01% | ▼ −2.48% | $0.1700 (−24.11%) |
Jun 26, 2026 17w ago | 6-K | $0.1110 $0.1310 | ▲ +18.02% | ▲ +15.85% | $0.1700 (+53.15%) |
Apr 13, 2026 27w ago | 6-K | $0.0410 $0.0480 | ▲ +17.07% | ▲ +13.78% | $0.1700 (+314.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers